BDBM513650 5-(((5-fluorobenzofuran-4-yl)methyl)amino)-8-(2-methylpyridin-3-yl)imidazo[1,2-c]pyrimidine-2-carboxamide::US11091495, Example 12::US11091495, Example 22::US11220509, Example 22::US11485738, Example 12
SMILES Cc1ncccc1-c1cnc(NCc2c(F)ccc3occc23)n2cc(nc12)C(N)=O
InChI Key InChIKey=SMHLMPSZVTVQDP-UHFFFAOYSA-N
Data 4 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 4 hits for monomerid = 513650
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 300nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:An aliquot of each serial dilution of test compound was added to deep 384 well plate using Acoustic Technology instrument (Echo 550, LabCyte) contain...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 300nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair